Sept 19 (Reuters) - Tectonic Therapeutic Inc :
* TECTONIC THERAPEUTIC ANNOUNCES FAVORABLE PHASE 1A SAFETY, TOLERABILITY AND PK/PD RESULTS FOR LEAD PROGRAM TX45
* TECTONIC THERAPEUTIC INC -TX45 WAS WELL-TOLERATED WITH NO OBSERVED IMMUNOGENICITY
* TECTONIC THERAPEUTIC INC - TX45 DEMONSTRATED A FAVORABLE PK/PD RELATIONSHIP WHICH WAS USED TO IDENTIFY DOSES FOR PHASE 2 CLINICAL TRIAL
* TECTONIC THERAPEUTIC INC -SCREENING FOR PHASE 2 APEX CLINICAL TRIAL HAS BEEN INITIATED AND TOPLINE RESULTS ARE ANTICIPATED IN 2026
Source text for Eikon: Further company coverage:
(Reuters.Briefs@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.